We are studying if specific markers can help identify patients who can safely stop their anti-TNF treatment while in remission. This may help tailor treatment plans for better health outcomes.
We are exploring a new method for managing antibiotics in patients with Ventilator-Associated Pneumonia in intensive care. This study aims to see if daily assessments can improve survival and reduce complications.
We are studying whether a 7-day antibiotic treatment is as effective as a 14-day treatment for kidney transplant recipients with acute pyelonephritis. This research aims to improve treatment options and patient safety.
We are studying a new cell therapy for children with transfusion-dependent β-thalassemia to see if it can improve their condition and reduce the need for blood transfusions. The trial will also assess the safety of this treatment.
We are studying whether telmisartan can lower liver pressure in patients with advanced chronic liver disease and portal hypertension. This trial will also assess its safety and impact on quality of life.
We are studying whether norfloxacin can lower portal hypertension in patients with decompensated cirrhosis. The trial also looks at its effects on liver-related complications and overall patient well-being.
We are studying the safety of edoxaban in patients with Portosinusoidal Vascular Disorder. The trial also explores its potential to prevent blood clots and improve quality of life.
We are studying how rimegepant affects migraine-related reactions in lean and obese individuals. The goal is to understand the relationship between body composition and migraine responses.
We are investigating whether reducing the dose of bleomycin in electrochemotherapy can still effectively treat skin cancers. This study aims to see if patients can benefit from less medication while achieving similar tumor response.
We are studying whether high doses of antiretroviral drugs can reduce the hidden HIV-1 reservoir in people living with HIV. This trial will also assess the safety and effects of the treatment on immune markers.
We are comparing two biologic treatments for severe uveitis in Behçet’s disease to see which one may better improve vision and reduce inflammation. This study will also evaluate the safety of both medications.
We are testing a combination of palbociclib and fulvestrant in women with advanced breast cancer who have not responded to prior treatments. The goal is to evaluate its effectiveness and safety for these patients.
We are studying a combination of treatments for patients with BRAF mutated melanoma and brain metastases. The goal is to see if this approach can help control the disease and improve survival.
We are testing a new chemotherapy method to prevent cancer spread in patients who have had surgery for high-risk colorectal cancer. This study will help us understand its effectiveness and impact on patients' quality of life.
We are studying the safety and effectiveness of brigatinib in children and young adults with ALK+ Anaplastic Large Cell Lymphoma and other solid tumors. This trial aims to find the best dose and understand how the drug works in these patients.
We are studying how different diabetes medications affect fat tissue function in people with type 2 diabetes. This research may help us understand which drug works best for improving health outcomes.
We are studying whether statin treatment guided by genetic risk can lower heart disease events in individuals at high risk. The trial will also look at how well patients accept this personalized approach and its effects on their health.
We are studying whether stopping Omalizumab after long-term treatment is as effective as continuing it for patients with well-controlled severe allergic asthma. This trial aims to assess asthma control and quality of life over time.
We are studying whether cortisone can help children with acute facial nerve paralysis recover better than a placebo. The trial will also look at safety and how the condition affects daily life.
We are studying whether multiple doses of oxytocin can improve social symptoms in children with autism and intellectual disability. The trial also looks at other behavioral changes and stress-related measurements.